Aurinia Adds Two Assets To Expand Its Immunology Pipeline

  • Aurinia Pharmaceuticals Inc AUPH has added two assets to expand its rare autoimmune and kidney-related disease pipeline.
  • The first program, AUR200, was acquired from privately-held Thunderbolt Pharma Inc
  • AUR200 is a recombinant Fc fusion protein designed to block B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL). 
  • BAFF and APRIL promote B cell survival and play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions.
  • Aurinia paid $750,000 upfront. Additionally, Thunderbolt will receive low single-digit sales-based royalties. 
  • AUR200 is in preclinical development, with IND submission expected by the end of 2022.
  • The second program, AUR300, was added via a licensing and research agreement with Riptide Bioscience Inc.
  • AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cells) via the macrophage mannose receptor CD206. 
  • Aurinia paid Riptide an upfront fee of $6 million.
  • Clinical development for AUR300 will commence in 1H of 2023.
  • Price Action: AUPH shares closed 4.68% lower at $14.46 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechM&ANewsHealth CareAsset SalesSmall CapGeneralautoimmune diseasesBriefsPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!